VERTEX PHARMACEUTICALS INC / MA Payments to Acquire Debt Securities, Available-for-sale
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Payments to Acquire Debt Securities, Available-for-sale of $4.86 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $2.36B, a 8.43% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $2.51B, a 52.22% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $1.23B, a 42.99% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $1.35B, a 2.83% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for fiscal 2025 was $6.40B, a 14.00% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for fiscal 2024 was $7.44B, a 96.44% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for fiscal 2023 was $3.79B, a 446.63% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire debt securities, available-for-sale for fiscal 2022 was $692.70M, a 31.14% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.36B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.86B 10-Q · filed 2026-08-04 | $6.09B derived: sum of 3 quarters · filed 2026-08-04 | $7.44B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $2.51B 10-Q · filed 2026-05-05 | $3.74B derived: sum of 2 quarters · filed 2026-05-05 | $5.08B derived: sum of 3 quarters · filed 2026-05-05 | $7.26B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $2.58B derived: sum of 2 quarters · filed 2026-02-13 | $4.75B derived: sum of 3 quarters · filed 2026-08-04 | $6.40B 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $1.35B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.52B derived: sum of 2 quarters · filed 2026-08-04 | $5.17B 10-Q · filed 2025-11-04 | $7.32B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $2.17B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.82B 10-Q · filed 2026-08-04 | $5.98B derived: sum of 3 quarters · filed 2026-08-04 | $7.36B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $1.65B 10-Q · filed 2026-05-05 | $3.81B derived: sum of 2 quarters · filed 2026-05-05 | $5.19B derived: sum of 3 quarters · filed 2026-05-05 | $6.49B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $2.16B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $3.54B derived: sum of 2 quarters · filed 2026-02-13 | $4.84B derived: sum of 3 quarters · filed 2026-02-13 | $7.44B 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $1.38B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.68B derived: sum of 2 quarters · filed 2025-11-04 | $5.28B 10-Q · filed 2025-11-04 | $6.27B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $1.30B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.90B 10-Q · filed 2025-08-05 | $4.88B derived: sum of 3 quarters · filed 2026-02-13 | $5.29B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $2.60B 10-Q · filed 2025-05-06 | $3.59B derived: sum of 2 quarters · filed 2026-02-13 | $3.99B derived: sum of 3 quarters · filed 2026-02-13 | $4.57B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $988.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.40B derived: sum of 2 quarters · filed 2026-02-13 | $1.97B derived: sum of 3 quarters · filed 2026-02-13 | $3.79B 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $407.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $981.40M derived: sum of 2 quarters · filed 2024-11-05 | $2.80B 10-Q · filed 2024-11-05 | $3.07B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $574.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $2.39B 10-Q · filed 2024-08-02 | $2.67B derived: sum of 3 quarters · filed 2025-02-13 | $2.86B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $1.82B 10-Q · filed 2024-05-07 | $2.09B derived: sum of 2 quarters · filed 2025-02-13 | $2.28B derived: sum of 3 quarters · filed 2025-02-13 | $2.39B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $274.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $464.80M derived: sum of 2 quarters · filed 2025-02-13 | $575.60M derived: sum of 3 quarters · filed 2025-02-13 | $692.70M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $189.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $300.70M derived: sum of 2 quarters · filed 2023-11-07 | $417.80M 10-Q · filed 2023-11-07 | $498.20M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $110.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $227.90M 10-Q · filed 2023-08-02 | $308.30M derived: sum of 3 quarters · filed 2024-02-15 | $516.60M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $117.10M 10-Q · filed 2023-05-02 | $197.50M derived: sum of 2 quarters · filed 2024-02-15 | $405.80M derived: sum of 3 quarters · filed 2024-02-15 | $523.80M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $80.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $288.70M derived: sum of 2 quarters · filed 2024-02-15 | $406.70M derived: sum of 3 quarters · filed 2024-02-15 | $528.20M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $208.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $326.30M derived: sum of 2 quarters · filed 2022-10-28 | $447.80M 10-Q · filed 2022-10-28 | $447.76M 10-Q · filed 2021-11-03 | $632.26M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | $118.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $239.50M 10-Q · filed 2022-08-05 | $239.46M 10-Q · filed 2021-07-30 | $423.96M derived: sum of 3 quarters · filed 2023-02-10 | $544.32M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $121.50M 10-Q · filed 2022-05-06 | $121.45M 10-Q · filed 2021-04-30 | $305.96M derived: sum of 2 quarters · filed 2023-02-10 | $426.32M derived: sum of 3 quarters · filed 2023-02-10 | $477.63M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $184.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $304.82M derived: sum of 2 quarters · filed 2023-02-10 | $356.13M derived: sum of 3 quarters · filed 2023-02-10 | $431.40M 10-K · filed 2023-02-10 | $431.40M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $120.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $171.67M derived: sum of 2 quarters · filed 2021-11-03 | $246.94M 10-Q · filed 2021-11-03 | $402.40M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $51.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $126.58M 10-Q · filed 2021-07-30 | $282.04M derived: sum of 3 quarters · filed 2022-02-09 | $400.14M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $75.27M 10-Q · filed 2021-04-30 | $230.73M derived: sum of 2 quarters · filed 2022-02-09 | $348.83M derived: sum of 3 quarters · filed 2022-02-09 | $484.25M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $155.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $273.56M derived: sum of 2 quarters · filed 2022-02-09 | $408.99M derived: sum of 3 quarters · filed 2022-02-09 | $537.20M 10-K · filed 2022-02-09 | $537.20M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $118.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $253.52M derived: sum of 2 quarters · filed 2020-10-30 | $381.74M 10-Q · filed 2020-10-30 | $484.29M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $135.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $263.64M 10-Q · filed 2020-07-31 | $366.19M derived: sum of 3 quarters · filed 2021-02-11 | $493.55M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $128.22M 10-Q · filed 2020-05-01 | $230.77M derived: sum of 2 quarters · filed 2021-02-11 | $358.13M derived: sum of 3 quarters · filed 2021-02-11 | $521.48M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $102.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $229.92M derived: sum of 2 quarters · filed 2021-02-11 | $393.26M derived: sum of 3 quarters · filed 2021-02-11 | $431.92M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $127.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $290.71M derived: sum of 2 quarters · filed 2019-10-31 | $329.37M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $163.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $202.00M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $38.65M 10-Q · filed 2019-05-01 | |||||||
| 2017-09-30 | $431.65M 10-Q · filed 2018-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |